anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objective: Many women are affected by pelvic floor disorders, such as stress urinary incontinence and pelvic organ prolapse. In recent years, these disorders have been treated with transvaginal mesh implant surgeries involving the vaginal insertion of woven netting. We explored women's experiences of transvaginal mesh implant surgery through a biopsychosocial lens. Design: We analysed women's submissions to an Australian Parliament Senate Inquiry on transvaginal mesh implant surgery using thematic analysis. Main Outcome Methods: One-hundred and fifty-three publicly available submissions detailing women's experiences of transvaginal mesh implant surgery to an Australian Parliament Senate Inquiry were analysed. Adverse and positive accounts were eligible for inclusion. Results: We generated nine themes in three categories relating to the Biopsychosocial Model: Physical Health - comprising three themes; Psychological Health - comprising two themes; and Social Wellbeing - comprising four themes. Physical, psychological and social experiences interacted, resulting in reduced quality of life for women. Conclusion: Most women who made submissions to an Australian government inquiry about transvaginal mesh implant surgery described devastating impacts on physical, psychological, and social wellbeing. We provide recommendations to guide psychologists in assisting women with adverse transvaginal mesh-related outcomes. Further research should explore women's long-term experiences of the various transvaginal mesh procedures.
Potassium chloride extended-release tablets are a solid oral dosage form of potassium chloride containing 600 mg, 750 mg and 1500 mg of potassium chloride, USP, equivalent to 8 mEq, 10mEq and 20 mEq of potassium, respectively, in a film-coated (not enteric-coated), wax matrix tablet.

The chemical name is potassium chloride, and the structural formula is KCl. Potassium chloride, USP, occurs as a white, granular powder or as colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol. 

The 8 mEq and 10 mEq tablets also contain castor oil, cellulosic polymers, colloidal silicon dioxide, D&C Yellow No. 10, magnesium stearate, paraffin, polyvinyl acetate, titanium dioxide, vanillin, and vitamin E. 

The 20 mEq tablets also contain castor oil, cellulosic polymers, colloidal silicon dioxide, magnesium stearate, paraffin, polyvinyl acetate, titanium dioxide, vanillin, and vitamin E.
There is only one group in this study. The patients of this group will go through procedures as follow: basic pre-treatment information collected,treatment include platinum-based chemotherapy and 3-D conformal radiotherapy, blood test during RT 6am every Monday and follow-up visits with treatment-induced injury assessed.
PURPOSE: A pharmaceutical composition containing an extract of Actinidia apolygama PLANCH. et MIXIM. as an effective ingredient is provided. It has excellent analgesic and anti-inflammatory properties and thus can be effectively used in reducing pain and inhibiting inflammation. CONSTITUTION: The pharmaceutical composition contains 0.5 to 50% by weight of an Actinidia apolygama extract, based on the total weight of the composition. The Actinidia apolygama extract is obtained by extracting Actinidia apolygama in water, lower alcohol such as ethanol or methanol, or its mixed solvent. A health supplementary food comprises an Actinidia apolygama extract and nutritionally acceptable food additives.
A 6-week online cognitive-behavioural treatment for insomnia. Each week focuses on a different topic consistent with the cognitive-behavioural theory of insomnia.
Each cycle lasts 6 weeks. Administration of cyclosporine and CPT-11 weekly for 4 weeks followed by a 2 week 'rest' period with no drug given. Cyclosporine is given by IV infusion at a dose of 5 mg/kg. CPT-11 is given by IV infusion at a dose of 60 mg/m2.
Motivational interviewing (MI) is a clinical technique used to enhance an individual's behavioral changes. The MI intervention shares a similar basis as the cognitive behavioral therapy based on the Stages of Change. It has been found effective for enabling individuals to tackle their problems in weight control, substance abuse, and smoking.

The proposed study focuses on facilitating individuals with chronic diseases such as high blood pressure and diabetes to adopt health behaviors. The technique employed to facilitate the behavioral changes is the MI. Previous literature has reported the positive effects of MI in patients with chronic diseases. For instance, promoting weight loss in overweight and obese individuals, improving physical activity self-management in adults with type II diabetes, and regulation in blood pressure level among hypertensive individuals. However, the applications of the MI are mostly via the face-to-face method. Other application methods such as telephone coaching, online synchronous chat and mobile app are delivered as the alternative for communication. Individuals are engaged to enhance or modify certain behaviors via such as instant text interaction with psychologists, messages generated from a predefined system, and messages from interactive tools based on one's situation. Positive intervention effects were observed in these alternative forms of MI in terms of successful weight loss from a mobile app and telephone coaching and smoking cessation from telephone coaching. However, drawbacks include decreased attendance and engagement for lengthy programs, technical issues in delivering messages, and over-simplification of materials. The purpose of this study, therefore, is to deliver the MI to the participants with the use of perceptual learning theories, and the differential focuses on the cognitive and affective components when viewing simple MI messages via an app, and we name it the e-MI.
PURPOSE: A pharmaceutical composition containing a fusion peptide having dhFas-1 domain and MMP substrate is provided to suppress infiltration of immunocytes and to prevent and treat inflammatory diseases. CONSTITUTION: A fusion peptide contains: dhFas-1 domain, MMP(matrix metalloproteinase) substrate, and RGD motif. The fusion peptide further contains a linker peptide having 1-5 amino acids between dhFas-1 domain and MMP substrate. The dhFas-1 domain has an amino acid sequence of sequence number 1 or 3. The linker peptide is VE, EF, VD, or VDG. A pharmaceutical composition for preventing and treating inflammatory diseases contains the fusion peptide as an active ingredient.
Hemodynamic Effects

Chronic continuous infusions of FLOLAN in patients with PAH/SSD were studied in a prospective, open, randomized trial of 12 weeks’ duration comparing FLOLAN plus conventional therapy (n = 56) with conventional therapy alone (n = 55). Except for 5 NYHA Functional Class II patients, all patients were either functional Class III or Class IV. In the controlled 12-week trial in PAH/SSD, for example, the dose increased from a mean starting dose of 2.2 ng/kg/min. During the first 7 days of treatment, the dose was increased daily to a mean dose of 4.1 ng/kg/min on Day 7 of treatment. At the end of Week 12, the mean dose was 11.2 ng/kg/min. The mean incremental increase was 2 to 3 ng/kg/min every 3 weeks.

Conventional therapy varied among patients and included some or all of the following: anticoagulants in essentially all patients, supplemental oxygen and diuretics in two-thirds of the patients, oral vasodilators in 40% of the patients, and digoxin in a third of the patients. A statistically significant increase in CI and statistically significant decreases in PAPm, RAPm, PVR, and SAPm after 12 weeks of treatment were observed in patients who received FLOLAN chronically compared with those who did not. Table 4 illustrates the treatment-related hemodynamic changes in these patients after 12 weeks of treatment.

Clinical Effects

Statistically significant improvement was observed in exercise capacity, as measured by the 6‑minute walk, in patients receiving continuous intravenous FLOLAN plus conventional therapy for 12 weeks compared with those receiving conventional therapy alone. Improvements were apparent in some patients at the end of the first week of therapy. Increases in exercise capacity were accompanied by statistically significant improvements in dyspnea and fatigue, as measured by the Borg Dyspnea Index and Dyspnea Fatigue Index. At Week 12, NYHA functional class improved in 21 of 51 (41%) patients treated with FLOLAN compared with none of the 48 patients treated with conventional therapy alone. However, more patients in both treatment groups (28/51 [55%] with FLOLAN and 35/48 [73%] with conventional therapy alone) showed no change in functional class, and 2/51 (4%) with FLOLAN and 13/48 (27%) with conventional therapy alone worsened.

No statistical difference in survival over 12 weeks was observed in patients with PAH/SSD treated with FLOLAN as compared with those receiving conventional therapy alone. At the end of the treatment period, 4 of 56 (7%) patients receiving FLOLAN died, whereas 5 of 55 (9%) patients receiving conventional therapy alone died.
PROBLEM TO BE SOLVED: To obtain a hemorrhoidal medicine useful for improving the intractable hemorrhoid high in repeatability by formulating a specific photosensitive pigment as an active ingredient. SOLUTION: This hemorrhoidal medicine for external use is obtained by compounding at least one of platonin of formula I and lumin of formula II as an active ingredient. The compounds are extremely low in toxicity and excellent in safety. The platonin of formula I or the lumin of formula II is used at a dose of 0.005-0.1 w/w% in the cases of external use liquids, ointments or creams, and at a dose of 0.6-2 g several times a day in the cases of ointments, etc., which are injected into anuses or rectums. The photosensitive pigment is contained in an amount of 0.005-5 mg in a suppository in the case of the suppository. The photosensitive pigment may sufficiently be triturated with sodium bicarbonate to prepare a trituration containing the pigment in an amount of about 0.1-5 w/w%. When used, the trituration is dissolved in warm water, etc.
Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence (NIRF-C) and standard of care intraoperative cholangiography. 2.5 mg of indocyanine green is injected 30-60 minutes prior to surgery. Visualization of the biliary tree during surgery is achieved with a near-infrared light source and camera.
Hypotension in adult patients undergoing general anesthesia is common. Many of the body's normal mechanisms to maintain adequate blood pressure in the non-anesthetized state are significantly altered by anesthetic agents, which may lead to hypotension. This can lead to hypoperfusion of vital organs, organ damage, and states of increased metabolic duress. In response to this it has become standard of care to attempt to maintain blood pressure levels within 20% of baseline in most patients under anesthesia. Maintaining the baseline blood pressure is important as patients may have pathology such as coronary artery disease, carotid stenosis, and renal artery stenosis, and hypotension may compromise the perfusion of these organs. Vasodilation also plays a key role in hypotension due to general anesthesia. Therefore, the intravenous (IV) administration of Ang II may be an effective treatment of hypotension in this patient population.The objective of this study is to determine the infusion rate of Ang II that is necessary to return systolic blood pressure (SBP) to within 5% of baseline or greater in patients with essential hypertension taking ACE inhibitors, ARBs, or different classes of antihypertensive agents and further to determine the plasma levels of different RAAS components
The etiology of temporomandibular disorders (TMDs) is remarkably diverse. This case report highlights the use of clear aligners as a probable cofactor of TMD in an adult patient. A 56-year-old woman who presented with a chief concern of crowding was missing teeth in both arches and had generalized tooth wear, an indistinct history of temporomandibular joint musculoskeletal pain, and a self-reported history of clenching. Based on the patient's preferences, clear aligner therapy (CAT) was initiated with a limited treatment goal of providing improved esthetics by reducing the overjet, expanding the arches, and aligning the anterior teeth. A few weeks into CAT, the patient developed acute masticatory facial pain. Therefore, the course of CAT was adjusted in favor of an individualized protocol to alleviate her occlusal symptoms until orthodontic treatment was completed. Dental providers must consider the potential contributory role of CAT in TMDs in patients who adapt poorly to occlusal changes and offer a patient-centered approach to manage the problem.
A process for the preparation of an antibacterially active carboxylic acid compound designated as MM 13902 and salts thereof, which substance MM 13902 is sold carbxylic acid characterised in that its pure di-sodium salt; (i) is highly soluble in water, soluble in methanol and substantially insolubel in chloroform, diethylether and hydro-carbons; (ii) in aqueous solution has an ultra-violet spectrum substnatially as shown in Fig. 1 of the accompanying drawings with absorption maxima at about 305 and 225 mm; (iii) when present at 0.4% w/w in a freshly prepared KBr disc has an infra-red absorption spectrum substantially as shown in Fig. 2, of the accompanying drawings with absorption maxima at inter alia about 3450, 2950, 1750, 1620, 1510, 1400 and 1260cm1; (iv) has an n.m.r. specturm substantially as shown in Fig. 3 of the accompanying drawings when taken in a freshly prepared solution in D2O with inter alia (a) a pair of low fiedl doubelts centred at approximately 2.85GAMMA and 4.00GAMMA with coupling constants of approxiamtely 14 Hz; (b) a doublet centered at approxiamtely 8.55 and (c0 a sharp signlet at approxiamtely 8.00; (v) has the following approxdiamte Rf values ethn run on a cellulose thiin layer chromatogrpahy system; (a) n_butanol/ isopropanol/ water-7:7:6 v/v; Rf=0.72 (b) isopropanol/water-7:3 v/v; Rf=0.85 (c) n-butanol/ethanol/water-7:7:6 v/v; Rf0.81 (d) n-propanol/water-4:1; Rf=0.75; (vi) has an I50 of between 0.001/ug/ml and 0.0001/ug/ml against the beta-lactamase of Escherichia coli B11; (vii) synergises the activity of ampicillin against organisms includign strains of Escherichia coli, Klebnsiella aerogenes, Proteus mirabills, Proteus morganii and Staphylococcus aureus Russell; which process comprises the aerobic grouth of a MM 13902 producing strain of Streptomyces in the presence of assimilable soruces of cabron, nitrogen, sulphur and mineral salts in a solid or semi-solid nutritive medium or in a liquid medium in which the nutrients are dissovled or supsended, at a temperature of 28+/-2degree C for 2 to 3 days and thereafter extracting the antibiotics opresent from the culture medium, either by initial absorption on to and then elution from active characoal or an ion-exchange resin cotnaining tertiary amino grous or quternary ammonium groups or by extracting into a solution of a lipophilic ammonium salt in a water immiscible soluvent at a temperature not exceeding 20degrees C and separatign the MM 13902 therefrom by column chromatograpohy either by using a cellulose or silica-gel column and eluting eith mixtures of water with water-miscible organic solvents or by using columns of ion-exchange resins containing tertiary amino grouups or quarternary ammonium groups and eluting with aqueous solutions of electrolytes buffered to appropriate neutrality. [IN141262A1]
Erythropoietin (EPO) is a glycoprotein synthesized in the kidneys which regulates the rate of proliferation and differentiation of red blood cell precursors. The main cause of anemia in children with chronic renal failure is deficiency of EPO production as a result of declining renal function. Recombinant human EPO (rHuEPO) is a synthetic erythropoietin that is structurally and functionally similar to naturally occuring EPO. Treatment of anemia using rHuEPO has been associated with an improvement in the quality of life for patients, likely attributable to an increased production in hemoglobin and a reduction of dilatation of the heart. Recently, an analogue of EPO with two extra oligosaccharide chins, darbepoetin alfa, has been described as having a more prolonged effect requiring less frequent dosing.

There are currently no data available on the efficacy of darbepoetin alfa administered every 14-28 days for children. The most common dosing schedules in the clinical trial at HSC are every 7, 10, and 14 days. Due to reports of increased pain associated with the SC injection, and confusion of caregivers when the 10 day dosing schedule is necessary, the goals of the current proposal are to: 1) Decrease the frequency of SC injections and 2)Eliminate the 10 day dosing schedule for the administration of Darbepoetin.
The inflammation causes the destroyed osseointegration at the implant-bone interface, significantly increasing the probability of implant loosening in osteoporotic patients. Currently, inhibiting the differentiation of M1 macrophages and the inflammatory response could be a solution to stabilize the microenvironment of implants. Interestingly, some natural products have anti-inflammatory and anti-polarization effects, which could be a promising candidate for stabilizing the implants' microenvironment in osteoporotic patients. This research aims to explore the inhibitory effect of Urolithin B(UB) on macrophage M1 polarization, which ameliorates inflammation, thus alleviating implant instability. We established an osteoporosis mouse model of implant loosening. The mouse tissues were taken out for morphological analysis, staining analysis, and bone metabolic index analysis. In in vitro experiments, RAW264.7 cells were polarized to M1 macrophages using lipopolysaccharide (LPS) and analyzed by immunofluorescence (IF) staining, Western blot (WB), and flow cytometry. The CSP100 plus chip experiments were used to explore the potential mechanisms behind the inhibiting effects of UB. Through observation of these experiments, UB can improve the osseointegration between the implants and femurs in osteoporotic mice and enhance the stability of implants. The UB can inhibit the differentiation of M1 macrophages and local inflammation via inhibiting the phosphorylation of VEGFR2, which can be further proved by the weakened inhibited effects of UB in macrophages with lentivirus-induced overexpression of VEGFR2. Overall, UB can specifically inhibit the activation of VEGFR2, alleviate local inflammation, and improve the stability of implants in osteoporotic mice.
Although palliative chemotherapy improved the outcome of patients with advanced Gastric Cancer, the prognosis for this group of patients remains poor. Tumor specific antigens and angiogenesis pathway are potential targets for immunotherapy. A cocktail of peptide vaccines is selected to overcome gastric cancer's heterogeneous and enhance the anti-tumor effect. Five HLA-A\*2402-binding peptide vaccines derived from tumor specific antigens and VEGFR1 are chosen based on the frequencies of their expressions in gastric cancer and the ability to induce specific cytotoxic T-lymphocytes. In preclinical model, both down regulation these targets with siRNA and active vaccination resulted in tumor regression. The purpose of the study is to evaluate the safety and optimal dosing schedule of a cancer vaccine cocktail, OTSGC-A24 targeting novel specific tumor antigens FOXM1, DEPDC1, KIF20A, URLC10 and VEGFR1 in advanced gastric cancer patients with HLA-2402 haplotype.
BACKGROUND: Rotavirus is the leading cause of severe diarrhea in infants and young children. Live attenuated vaccines can lead to horizontal transmission with the risk of vaccine-derived disease in contacts. Transmission of pentavalent human-bovine reassortant rotavirus vaccine (RV5) strains leading to clinical disease was not well evaluated in the pivotal clinical trials, and only a few case reports have been described in the literature.
METHODS: We performed a systematic literature review to investigate secondary transmission of RV5 strains to unvaccinated subjects globally. We searched Embase, Medline for English papers, CNKI, Wan Fang for Chinese papers, and other resources (i.e., conference papers with full text) from January 2005 to June 2021. Eligibility criteria for inclusion were original articles based on non-interventional studies (case-control studies, cohort studies, cross-sectional studies) using RV5 strain transmission as outcomes. Other study or publication types were excluded, such as pre-clinical studies, interventional studies and case reports. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was used, and study quality was assessed using the Newcastle-Ottawa Scale (NOS) for cohort studies and the JBI checklist for cross-sectional studies to assess the risk of bias.
RESULTS: The search generated 2,089 articles in total. Seven articles met all inclusion criteria, including six cohort studies and one cross-sectional study. All studies underwent quality assessment and complied with the quality criteria of the NOS or JBI checklist, respectively. Overall, none of the seven studies identified RV5 vaccine-type transmission to an unvaccinated population, in either hospitals or nurseries under a close contact environment. One study reported that 1% of unvaccinated infants had gastrointestinal symptoms, but all symptoms were attributed to other clinical conditions.
CONCLUSIONS: We found no evidence of horizontal transmission of RV5 strains to unvaccinated infants in a context of a limited amount and the descriptive nature of the identified studies.
The invention relates to a preparation method of a high-uniformity vitamin AD pellet and the vitamin AD pellet. Specifically, the vitamin AD pellets comprise vitamin A and vitamin D2, wherein each 1 gram of the pellets comprise 2-20 ten thousand I.U. vitamin A and 0.2-2 ten thousand I.U. vitamin D 2 . The preparation method of the vitamin AD micro-pill comprises the following steps of dissolving an oily material to obtain an oily liquid, dissolving an aqueous material to obtain an aqueous liquid, emulsifying the mixed material in a vacuum emulsifying machine to obtain an emulsion, dripping the emulsion into the solidified oil by a pill dripping machine, cooling and solidifying to form a micro-pill, filtering out the micro-pill, and drying to obtain the vitamin AD micro-pill. The vitamin AD micro-pill has excellent uniformity in terms of not only three-dimensional size, but also weight and active ingredient content.